

Fenlu Zhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8504140/publications.pdf>

Version: 2024-02-01

18
papers

519
citations

1163117

8
h-index

1125743

13
g-index

18
all docs

18
docs citations

18
times ranked

879
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2021, 62, 229-233.	1.3	0
2	Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. <i>Nature Medicine</i> , 2020, 26, 1569-1575.	30.7	266
3	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1876-1885.	2.0	4
4	Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 4465-4465.	1.4	6
5	Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2510-2510.	1.6	35
6	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft- <i>versus</i> -host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018, 103, 717-727.	3.5	38
7	Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. <i>Cytotherapy</i> , 2018, 20, 394-406.	0.7	89
8	A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 4193-4193.	1.4	27
9	Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL. <i>Blood</i> , 2018, 132, 4553-4553.	1.4	5
10	CAR-T Cell Production Using the Clinimacs® Prodigy System. <i>Blood</i> , 2016, 128, 5724-5724.	1.4	12
11	Pilot Study of Prognostic Impact of Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Plasma Levels of CXC-Chemokines (CXCL-4 and CXCL-7) in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 4678-4678.	1.4	0
12	Hydroxyethyl starch as a substitute for dextran 40 for thawing peripheral blood progenitor cell products. <i>Cytotherapy</i> , 2015, 17, 1813-1819.	0.7	15
13	Day 100 Absolute Lymphocyte Count (ALC) Predicts Risk of Serious Infections in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2015, 126, 3168-3168.	1.4	0
14	Generation of cytotoxic T-cell lines using overlapping pentadecapeptides derived from conserved regions of the adenovirus hexon protein. <i>Journal of General Virology</i> , 2010, 91, 1577-1589.	2.9	5
15	Allo-Reactive Potential of Multi-Virus Specific Cytotoxic T Cell Lines Recognizing Adenovirus Hexon, Cytomegalovirus pp65 and Epstein Barr Virus.. <i>Blood</i> , 2009, 114, 5121-5121.	1.4	0
16	Generation of Multi-Specific CTL Lines Using Overlapping Pentadecapeptide Pools of Aspergillus f16 and Adenovirus Hexon Antigens Presented on Epstein Barr Virus-Transformed B Cells as Antigen Presenting Cells.. <i>Blood</i> , 2006, 108, 2927-2927.	1.4	0
17	Interactions between helper T-cell epitopes of hepatitis C virus. <i>Vaccine</i> , 2005, 23, 3572-3580.	3.8	4
18	Functionally distinct helper T-cell epitopes of HCV and their role in modulation of NS3-specific, CD8+/tetramer positive CTL. <i>Human Immunology</i> , 2002, 63, 710-718.	2.4	13